Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$115.46 USD
+0.79 (0.69%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $116.08 +0.62 (0.54%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Zimmer Biomet (ZBH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$126.04 | $145.00 | $107.00 | 9.92% |
Price Target
Based on short-term price targets offered by 24 analysts, the average price target for Zimmer Biomet comes to $126.04. The forecasts range from a low of $107.00 to a high of $145.00. The average price target represents an increase of 9.92% from the last closing price of $114.67.
Analyst Price Targets (24)
Broker Rating
Zimmer Biomet currently has an average brokerage recommendation (ABR) of 2.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 27 brokerage firms. The current ABR compares to an ABR of 2.56 a month ago based on 27 recommendations.
Of the 27 recommendations deriving the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 25.93% and 7.41% of all recommendations. A month ago, Strong Buy made up 25.93%, while Buy represented 7.41%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ZBH.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 8 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 16 | 16 | 16 | 16 | 15 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.56 | 2.56 | 2.56 | 2.56 | 2.48 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/20/2024 | Canaccord Genuity | William J Plovanic | Hold | Hold |
8/8/2024 | Robert W. Baird & Co. | Jeffrey D Johnson | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | UBS | Danielle Antalffy | Strong Sell | Strong Sell |
8/8/2024 | Raymond James | Jayson T Bedford | Moderate Buy | Moderate Buy |
8/8/2024 | Evercore Partners | Vijay Kumar | Hold | Hold |
8/8/2024 | Needham & Company | Michael Matson | Hold | Hold |
8/8/2024 | Wells Fargo Securities | Lawrence H Biegelsen | Hold | Hold |
8/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/16/2024 | Roth Capital Partners | Jason Wittes | Hold | Hold |
7/10/2024 | Not Identified | Not Identified | Hold | Hold |
7/1/2024 | Piper Sandler | Matthew O'Brien | Strong Buy | Hold |
5/31/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
5/30/2024 | Goldman Sachs | David H Roman | Not Available | Hold |
5/30/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
5/21/2024 | Argus Research Corp. | David A Toung | Not Available | Strong Buy |
5/3/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/2/2024 | Not Identified | Not Identified | Hold | Hold |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/2/2024 | Not Identified | Not Identified | Hold | Hold |
4/1/2024 | Cowen & Co. | Joshua T Jennings | Hold | Hold |
1/7/2024 | BTIG | Ryan Zimmerman | Strong Buy | Strong Buy |
11/13/2023 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.56 |
ABR (Last week) | 2.56 |
# of Recs in ABR | 27 |
Average Target Price | $126.04 |
LT Growth Rate | 7.00% |
Industry | Medical - Products |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | 1.79 |